Rollover Study for Patients With Sickle Cell Disease Who Have Completed a Prior Novartis-Sponsored Crizanlizumab Study

RECRUITING

Novartis Investigative Site, Muscat

COMPLETED

Novartis Investigative Site, Brussels

RECRUITING

Novartis Investigative Site, Laken

RECRUITING

Novartis Investigative Site, Tripoli

RECRUITING

Novartis Investigative Site, Liège

COMPLETED

Novartis Investigative Site, Orbassano

RECRUITING

Childrens National Hospital, Washington D.C.

COMPLETED

East Carolina University, Greenville

COMPLETED

East Carolina University, Greenville

RECRUITING

Novartis Investigative Site, Madrid

RECRUITING

Augusta University Georgia, Augusta

WITHDRAWN

Novartis Investigative Site, Antakya Hatay

RECRUITING

Novartis Investigative Site, Padua

RECRUITING

University Of Alabama, Birmingham

RECRUITING

Novartis Investigative Site, Heidelberg

ACTIVE_NOT_RECRUITING

Novartis Investigative Site, Paris

COMPLETED

Novartis Investigative Site, Paris

COMPLETED

Cook Childrens Medical Center, Fort Worth

COMPLETED

Novartis Investigative Site, Créteil

ACTIVE_NOT_RECRUITING

Novartis Investigative Site, Montería

ACTIVE_NOT_RECRUITING

Novartis Investigative Site, Santiago de Cali

RECRUITING

Childrens Hospital of Philadelphia, Philadelphia

TERMINATED

Novartis Investigative Site, Salvador

TERMINATED

Novartis Investigative Site, Ribeirão Preto

TERMINATED

Novartis Investigative Site, São Paulo

RECRUITING

Novartis Investigative Site, Beirut

COMPLETED

Novartis Investigative Site, Barcelona

ACTIVE_NOT_RECRUITING

Novartis Investigative Site, Adana

ACTIVE_NOT_RECRUITING

Novartis Investigative Site, Adana